Bellicum Pharmaceuticals, Inc.
- Jurisdiction
United States - LEI
529900HBXNLX2TBQZQ65 - ISIN
US0794814048 (BLCM )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€1.29M - Gross margin
100.0% - EBIT
-€19.66M - EBIT margin
-1,528.7% - Net income
-€18.59M - Net margin
-1,445.4%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: March 30, 2021 (Q4 2020)